Stock listing
NASDAQ:PALI Palisade Bio, Inc. Stock
Home listing (NASDAQ) of Palisade Bio, Inc.
Follow Palisade Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PALI
$0.84 USD -0.10 (-10.8%)
Close on Nov 20, 2026
- Day range
- $0.838 – $0.96 USDNov 20, 2026
- Volume
- 3.19M sharesNov 20, 2026
- Market cap
- $150.6M USDAt the close on Nov 20, 2026 · price × 179.3M shares outstanding
- 52-week range
- $0.838 – $2.86 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.61M USDMedian day 2.07M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PALI · Home | $0.84 USD | -0.102 (-10.8%) | 3,190,610 | $0.911 | $0.96 | $0.838 | $0.942 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PALI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.84 | -0.102 | -10.8% | $0.911 | $0.96 | $0.838 | 3,190,610 | |
| $0.942 | -0.068 | -6.7% | $1.00 | $1.005 | $0.939 | 5,304,544 | |
| $1.01 | -0.02 | -1.9% | $1.00 | $1.036 | $0.99 | 1,952,612 | |
| $1.03 | -0.09 | -8.0% | $1.09 | $1.111 | $1.01 | 1,664,788 | |
| $1.12 | -0.02 | -1.8% | $1.15 | $1.15 | $1.08 | 1,458,544 | |
| $1.14 | -0.03 | -2.6% | $1.16 | $1.175 | $1.13 | 985,370 | |
| $1.17 | +0.04 | +3.5% | $1.11 | $1.185 | $1.11 | 2,964,152 | |
| $1.13 | -0.06 | -5.0% | $1.18 | $1.20 | $1.11 | 1,618,816 | |
| $1.19 | +0.06 | +5.3% | $1.16 | $1.23 | $1.145 | 1,407,053 | |
| $1.13 | -0.03 | -2.6% | $1.14 | $1.18 | $1.10 | 2,029,638 | |
| $1.16 | -0.09 | -7.2% | $1.22 | $1.225 | $1.10 | 2,591,414 | |
| $1.25 | +0.02 | +1.6% | $1.26 | $1.30 | $1.21 | 2,014,098 | |
| $1.23 | +0.11 | +9.8% | $1.14 | $1.245 | $1.13 | 18,627,703 | |
| $1.12 | -0.04 | -3.4% | $1.20 | $1.20 | $1.08 | 3,065,248 | |
| $1.16 | -0.03 | -2.5% | $1.18 | $1.20 | $1.12 | 3,090,528 | |
| $1.19 | 0.00 | 0.0% | $1.20 | $1.25 | $1.15 | 3,499,620 | |
| $1.19 | -0.01 | -0.8% | $1.22 | $1.22 | $1.10 | 15,113,518 | |
| $1.20 | -0.03 | -2.4% | $1.22 | $1.255 | $1.17 | 6,011,066 | |
| $1.23 | -0.10 | -7.5% | $1.33 | $1.34 | $1.21 | 1,702,019 | |
| $1.33 | -0.02 | -1.5% | $1.35 | $1.37 | $1.28 | 1,153,900 | |
| $1.35 | -0.05 | -3.6% | $1.38 | $1.41 | $1.35 | 1,111,800 | |
| $1.40 | -0.03 | -2.1% | $1.44 | $1.46 | $1.39 | 1,432,800 | |
| $1.43 | +0.09 | +6.7% | $1.39 | $1.48 | $1.34 | 2,817,400 | |
| $1.34 | -0.07 | -5.0% | $1.41 | $1.46 | $1.32 | 1,834,400 | |
| $1.41 | -0.13 | -8.4% | $1.55 | $1.56 | $1.40 | 3,888,900 | |
| $1.54 | +0.06 | +4.1% | $1.50 | $1.56 | $1.48 | 1,817,600 | |
| $1.48 | +0.01 | +0.7% | $1.45 | $1.51 | $1.38 | 4,162,500 | |
| $1.47 | -0.12 | -7.5% | $1.56 | $1.58 | $1.46 | 1,587,900 | |
| $1.59 | +0.05 | +3.2% | $1.53 | $1.63 | $1.51 | 1,571,700 | |
| $1.54 | +0.09 | +6.2% | $1.49 | $1.57 | $1.47 | 1,840,400 | |
| $1.45 | -0.03 | -2.0% | $1.47 | $1.48 | $1.38 | 2,083,900 | |
| $1.48 | -0.01 | -0.7% | $1.46 | $1.48 | $1.44 | 825,200 | |
| $1.49 | +0.03 | +2.1% | $1.51 | $1.55 | $1.47 | 1,972,700 | |
| $1.46 | +0.02 | +1.4% | $1.44 | $1.48 | $1.41 | 1,595,700 | |
| $1.44 | +0.01 | +0.7% | $1.46 | $1.48 | $1.43 | 1,993,500 | |
| $1.43 | +0.08 | +5.9% | $1.39 | $1.46 | $1.37 | 2,644,700 | |
| $1.35 | -0.10 | -6.9% | $1.44 | $1.46 | $1.32 | 4,765,200 | |
| $1.45 | -0.05 | -3.3% | $1.54 | $1.55 | $1.42 | 2,164,000 | |
| $1.50 | +0.05 | +3.4% | $1.45 | $1.53 | $1.43 | 8,683,300 | |
| $1.45 | -0.12 | -7.6% | $1.57 | $1.59 | $1.45 | 5,780,700 | |
| $1.57 | -0.03 | -1.9% | $1.60 | $1.60 | $1.50 | 3,257,200 | |
| $1.60 | -0.09 | -5.3% | $1.69 | $1.70 | $1.59 | 2,941,400 | |
| $1.69 | 0.00 | 0.0% | $1.71 | $1.71 | $1.60 | 4,982,600 | |
| $1.69 | +0.10 | +6.3% | $1.64 | $1.69 | $1.60 | 3,574,200 | |
| $1.59 | -0.11 | -6.5% | $1.68 | $1.72 | $1.59 | 6,869,400 | |
| $1.70 | +0.01 | +0.6% | $1.75 | $1.76 | $1.65 | 5,396,600 | |
| $1.69 | -0.33 | -16.3% | $2.04 | $2.04 | $1.67 | 8,407,600 | |
| $2.02 | -0.03 | -1.5% | $2.05 | $2.06 | $1.96 | 4,489,400 | |
| $2.05 | -0.01 | -0.5% | $2.05 | $2.11 | $2.02 | 1,813,500 | |
| $2.06 | +0.05 | +2.5% | $2.05 | $2.10 | $2.02 | 2,399,400 | |
| $2.01 | -0.04 | -2.0% | $2.05 | $2.11 | $2.01 | 2,646,400 | |
| $2.05 | -0.15 | -6.8% | $2.17 | $2.21 | $2.05 | 2,774,700 | |
| $2.20 | +0.11 | +5.3% | $2.09 | $2.24 | $2.08 | 3,529,800 | |
| $2.09 | +0.04 | +2.0% | $2.03 | $2.12 | $2.00 | 1,755,300 | |
| $2.05 | +0.06 | +3.0% | $2.01 | $2.05 | $1.97 | 1,086,600 | |
| $1.99 | +0.03 | +1.5% | $1.96 | $2.01 | $1.95 | 730,700 | |
| $1.96 | +0.01 | +0.5% | $1.96 | $1.98 | $1.92 | 879,400 | |
| $1.95 | -0.05 | -2.5% | $2.02 | $2.02 | $1.93 | 1,645,100 | |
| $2.00 | -0.11 | -5.2% | $2.10 | $2.11 | $1.99 | 2,127,100 | |
| $2.11 | -0.02 | -0.9% | $2.12 | $2.16 | $2.10 | 899,100 | |
| $2.13 | +0.06 | +2.9% | $2.06 | $2.14 | $2.03 | 1,190,100 | |
| $2.07 | +0.06 | +3.0% | $2.02 | $2.10 | $1.98 | 2,068,108 | |
| $2.01 | -0.09 | -4.3% | $2.10 | $2.10 | $2.00 | 1,618,511 | |
| $2.10 | +0.04 | +1.9% | $2.09 | $2.14 | $2.08 | 1,070,300 | |
| $2.06 | -0.10 | -4.6% | $2.14 | $2.15 | $2.03 | 1,324,900 |
Splits
5 splits since 2017 · NASDAQ:PALI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation | |
| 1-for-50 | Consolidation | |
| 1-for-6 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-13 | Consolidation |
- Ticker
- NASDAQ:PALI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
Latest news
Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
Nov 10, 2026
Closed $1.17 (+3.5%) on Nov 11, 2026
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
Oct 28, 2026
Closed $1.19 (-0.8%) on Oct 28, 2026
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
Oct 20, 2026
Closed $1.43 (+6.7%) on Oct 20, 2026
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
Oct 12, 2026
Closed $1.59 (+3.2%) on Oct 12, 2026
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Sep 28, 2026
Closed $1.50 (+3.4%) on Sep 28, 2026
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Sep 23, 2026
Closed $1.60 (-5.3%) on Sep 23, 2026
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
Sep 22, 2026
Closed $1.69 (0.0%) on Sep 22, 2026
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Sep 21, 2026
Closed $1.69 (+6.3%) on Sep 21, 2026
Palisade Bio to Participate in Upcoming Investor Conferences
Sep 3, 2026
Closed $2.05 (+3.0%) on Sep 3, 2026
Palisade Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 152 in all · newest Nov 10, 2026 · oldest 2021
- Decks
- 45 decks · latest September 2025
Where Palisade Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PALI · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PALI | BOATS | United States | USD |
| gettex:7NS0 | gettex | Germany | EUR |
| Frankfurt:7NS0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A4098S | Lang & Schwarz | Germany | EUR |
| Munich:7NS0 | Munich | Germany | EUR |
Valuation
EV/sales 73.9× against a median of 39.0×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $36.96M USD
- P/E
- Loss
- EV/sales
- 73.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.41
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Palisade Bio, Inc. · NASDAQ:PALI | US$150.6M | US$36.96M | n/a | 73.9× | n/a | 1.3× | n/a | 0.0× | 1.41 |
| BioVersys AG · SIX:BIOV | US$154.1M | US$97.45M | n/a | 102× | n/a | 2.9× | n/a | 0.5× | n/a |
| InflaRx N.V. · NASDAQ:IFRX | US$153.3M | US$135.7M | n/a | 4,215× | n/a | 19.5× | n/a | 0.0× | 1.61 |
| Polaris Group · TWSE:6550 | US$153.0M | US$154.8M | n/a | 75.1× | n/a | 1.1× | n/a | 0.5× | n/a |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541 | US$152.0M | US$64.59M | n/a | 2.9× | n/a | 1.6× | −141.7% | 0.6× | n/a |
| Saniona AB · OMXSTO:SANION | US$151.6M | US$104.0M | 8.4× | 2.5× | 5.2× | 2.8× | 43.2% | 0.0× | n/a |
| Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN | US$150.3M | US$80.67M | n/a | n/a | n/a | 4.9× | n/a | 0.0× | 1.95 |
| Veraxa Biotech AG · NASDAQ:VRXA | US$147.1M | US$145.1M | n/a | 5,202× | n/a | n/a | n/a | n/a | 1.11 |
| ProQR Therapeutics N.V. · NASDAQ:PRQR | US$146.8M | US$49.73M | n/a | 2.2× | n/a | 2.0× | −210.7% | 0.2× | 1.73 |
| ALX Oncology Holdings Inc. · NASDAQ:ALXO | US$146.6M | US$9.57M | n/a | n/a | n/a | 1.2× | n/a | 0.1× | 0.68 |
| Bicycle Therapeutics PLC · NASDAQ:BCYC | US$146.1M | −US$323.8M | n/a | −3.9× | n/a | 0.3× | −169.8% | 0.0× | 1.59 |
| Median of the others | US$151.0M | US$89.06M | 8.4× | 39.0× | 5.2× | 2.0× | −155.7% | 0.1× | 1.60 |
Forecasts
7 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.90 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.24 · 2 analysts
- Revenue, year to Dec 2026
- 500K · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| JD Finley | Chief Executive Officer and Director |
| Mitch Jones | President and Chief Medical Officer |
| Julien E. Capers | General Counsel & Corporate Secretary |
| Ramesh Donthamsetty | Head of IR and Corporate Strategy |
| Adarsh Patel | Head of Chemistry, Manufacturing and Controls (CMC) |
| Daniel J. Larkins | Head of Global Regulatory Affairs |
| Dawn Louro | Head of Clinical Operations |
| James Izanec | Head of Clinical Development |
| Joerg Heyer | Head of Translational Science and Medicine |
| Ryker Willie | Head of Finance and Corporate Controller |
Board
| Director | Role |
|---|---|
| Donald A. Williams | Chairman of the Board |
| Binxian Wei | Director |
| Emil Chuang | Director |
| JD Finley | Chief Executive Officer and Director |
| Jordan Zwick | Director |
| Robert Baltera | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +3.5% |
| Q2 2026 | Aug 10, 2026 · After close | +1.9% |
| Q1 2026 | May 13, 2026 | −5.7% |
| Q4 2025 | Mar 25, 2026 | −2.0% |
| Q3 2025 | Nov 10, 2025 · After close | +2.8% |
| Q2 2025 | Aug 11, 2025 · After close | +1.4% |
| Q1 2025 | May 12, 2025 · After close | −5.2% |
| Q4 2024 | Mar 25, 2025 · Before open | −1.4% |
| Q3 2024 | Nov 12, 2024 · Before open | −4.4% |
| Q2 2024 | Aug 12, 2024 · After close | +1.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | +0.3% |
| Q4 2023 | Mar 26, 2024 · After close | +8.1% |
| Q3 2023 | Nov 9, 2023 · After close | +1.9% |
| Q2 2023 | Aug 10, 2023 · After close | +2.9% |
| Q1 2023 | May 11, 2023 · After close | −1.9% |
| Q4 2022 | Mar 22, 2023 · After close | −2.9% |
| Q3 2022 | Nov 14, 2022 · Before open | 0.0% |
| Q2 2022 | Aug 15, 2022 · Before open | −4.2% |
| Q1 2022 | May 13, 2022 · Before open | +8.5% |
| Q4 2021 | Mar 17, 2022 · After close | −12.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| STAR Annual Meeting 2025 | Conference | 18 slides | September 2025 |
| 8th Anti-Fibrotic Drug Development Summit (November 2024) | Conference | 17 slides | November 2024 |
| Investor Presentation (April 2024) | Investor deck | 25 slides | April 2024 |
| IBD Innovate 2024 | Conference | 27 slides | April 2024 |
| Investor Presentation (January 2024) | Investor deck | 25 slides | January 2024 |
| Investor Presentation (November 2023) | Investor deck | 26 slides | Nov 7, 2023 |
| Investor Presentation (February 2023) | Investor deck | 24 slides | February 2023 |
| IPO Roadshow (July 2022) | IPO roadshow | 34 slides | Jul 25, 2022 |
| Investor Presentation (May 2022) | Investor deck | 46 slides | May 3, 2022 |
| SAGES 2022 | Conference | 24 slides | Mar 16, 2022 |
All 45 decks
Financings
| Raise | Date |
|---|---|
| Strategic investment of equity Announced: up to US$500,000 Buyers: Crohn’s & Colitis Foundation (IBD Ventures program) (strategic equity investment of up to $500,000) Use of proceeds: Continued clinical and mechanistic development of PALI-2108 for fibrostenotic Crohn's disease and ulcerative colitis | Jan 7, 2026 |
| Public offering of common stock (or common stock equivalents) Closed: US$138M raised · US$0.7 a share · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Buyers: B Group Capital (led the offering); Columbia Threadneedle Investments (led the offering); Adage Capital Partners LP (significant participation); ADAR1 Capital Management (significant participation); Boxer Capital Management (significant participation); Coastlands Capital (significant participation); Deep Track Capital (significant participation); Janus Henderson Investors (significant participation); Octagon Capital (significant participation); Perceptive Advisors (significant participation); RA Capital Management (significant participation); Squadron Capital Management (significant participation) Use of proceeds: To support the upcoming Phase 2 clinical development program for PALI-2108 in ulcerative colitis | Oct 2, 2025 |
| Warrant exercise of existing warrants to purchase common stock Announced: about US$3.9M · US$0.9047 a share · Warrants at US$0.9047 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Working capital and general corporate purposes | Jul 24, 2025 |
| Public offering of class A Units and Class B Units (common stock or prefunded warrants with common warrants) Announced: about US$5M · US$1.525 a unit · Warrants at US$1.4 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Phase 1 clinical trial of PALI-2108, pre-clinical studies, research and development, and working capital | Dec 12, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 250.0K | 0 | 0 | 13.5K | 15.4K | 260.0K | 260.0K | 16.2K |
| Cost of revenue | 3.00K | 3.00K | 4.00K | 167.0K | 168.0K | 146.0K | -990.0K | |||
| Gross profit | -3.00K | -3.00K | 250.0K | -167.0K | -168.0K | -146.0K | 15.4K | 1.25M | 260.0K | 16.2K |
| Research and development | 10.2M | 16.0M | 6.89M | 6.55M | 2.43M | 2.02M | 4.06M | 3.96M | 8.10M | 13.2M |
| Selling, general and administrative | 7.86M | 5.80M | 6.20M | 8.76M | 9.31M | 6.20M | 7.27M | 3.57M | 5.47M | 7.50M |
| Operating income | -18.1M | -14.9M | -13.1M | -15.7M | -41.9M | -9.30M | -8.63M | -8.26M | -13.3M | -20.6M |
| Depreciation and amortization | 3.00K | 3.00K | 4.00K | 3.00K | 2.00K | 3.00K | 143.9K | 185.8K | 289.2K | 337.5K |
| EBITDA | -18.1M | -14.9M | -13.1M | -15.7M | -41.9M | -9.29M | -8.49M | -8.07M | -13.0M | -20.3M |
| Interest expense | 10.0K | 12.0K | 15.0K | 13.0K | 2.40M | 235.0K | 8.92K | 7.70K | 159.1K | 1.14M |
| Income before tax | -16.8M | -14.4M | -12.3M | -14.3M | -26.6M | -10.3M | -8.35M | -4.92M | -15.7M | -21.1M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 1.00K | 289.0K | 3.34M | -2.20M | 0 |
| Net income | -16.8M | -14.4M | -12.3M | -14.3M | -26.6M | -10.3M | -8.35M | -4.92M | -15.7M | -21.1M |
| Earnings per share, basic | -0.30 | -10.19 | -27.01 | -16.53 | -142.95 | -3.72 | -3.80 | -7.54 | -1.20 | -2.53 |
| Earnings per share, diluted | -0.30 | -10.19 | -27.01 | -16.53 | -169.74 | -3.72 | -3.80 | -7.54 | -1.20 | -2.53 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 133.4M | 9.82M | 12.4M | 12.4M | 10.5M | 713.0K | 5.11M | 5.79M | 6.67M | 15.2M |
| Short-term investments | 16.0K | 5.00M | 5.00M | |||||||
| Receivables | 0 | 0 | 148.0K | 0 | 0 | 59.0K | 21.1K | 294.1K | 312.8K | 10.5K |
| Inventory | 12.0K | -1.44M | -150.0K | -2.23M | ||||||
| Current assets | 134.2M | 10.5M | 13.3M | 14.7M | 11.5M | 896.0K | 5.65M | 6.51M | 12.4M | 20.9M |
| Property, plant and equipment | 0 | 3.00K | 10.0K | 10.0K | 3.00K | 5.00K | 41.0K | 90.3K | 172.9K | 269.6K |
| Total assets | 134.3M | 10.9M | 14.1M | 15.8M | 12.5M | 3.02M | 6.58M | 7.68M | 13.9M | 22.6M |
| Accounts payable | 767.0K | 1.10M | 698.0K | 1.76M | 1.32M | 2.54M | 824.4K | 832.6K | 875.1K | 2.34M |
| Current liabilities | 4.64M | 3.24M | 2.59M | 3.01M | 2.50M | 8.08M | 1.22M | 1.05M | 1.51M | 7.33M |
| Long-term debt | 0 | 94.0K | ||||||||
| Total debt | 71.0K | 169.0K | 369.0K | 404.0K | 87.0K | 1.14M | 288.5K | 5.04M | 3.71M | |
| Total liabilities | 4.96M | 3.39M | 2.74M | 3.28M | 5.15M | 10.1M | 1.46M | 1.63M | 5.37M | 11.3M |
| Shareholders' equity | 129.4M | 7.49M | 11.3M | 12.5M | 7.37M | -16.6M | -8.33M | 6.05M | 8.52M | 11.3M |
| Shares outstanding | 159.4M | 2.77M | 618.1K | 2.94M | 284.8K | 2.77M | 3.87M | 910.3K | 15.2M | 11.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10.8M | -12.2M | -11.1M | -13.4M | -14.8M | -4.77M | -7.26M | -7.69M | -13.4M | -15.6M |
| Capital spending | 0 | 0 | -4.00K | -10.0K | 0 | -6.00K | -6.00K | -1.71K | -11.4K | -98.1K |
| Free cash flow | -10.8M | -12.2M | -11.1M | -13.4M | -14.8M | -4.77M | -7.26M | -7.69M | -13.4M | -15.7M |
| Cash from investing | 0 | -4.00K | -10.0K | -54.0K | -6.00K | 3.92M | 5.00M | -94.0K | 2.36M | |
| Cash from financing | 134.4M | 9.58M | 11.2M | 15.3M | 24.6M | 1.89M | 6.59M | 1.81M | 4.99M | 23.7M |
| Dividends paid | -99.0K | |||||||||
| Share buybacks | 19.0K | 11.0K | 17.0K | -99.0K | 14.7M | 6.55M | 1.83M | 8.74M | 28.1M | |
| Change in cash | 123.6M | -2.61M | 49.0K | 1.89M | 9.78M | -2.88M | -672.2K | -887.8K | -8.52M | 10.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 10, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | May 27, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | May 22, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 19, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 19, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | May 12, 2026 | Offer document | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 20, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 8, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 4, 2025 | Meeting outcome | SEC |
| S-8 · Registration statement for employee plans | Nov 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 4/A · Change in ownership, amended | Nov 6, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 6, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 6, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Nov 3, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 22, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 20, 2025 | Meeting outcome | SEC |
| PRE 14A · Preliminary proxy statement | Oct 20, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 16, 2025 | Current report | SEC |
| 8-K · Current report | Oct 9, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 9, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 9, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 7, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Oct 7, 2025 | Meeting notice | SEC |
| 424B4 · Prospectus | Oct 2, 2025 | Offer document | SEC |
| S-1MEF · Registration of more shares for the same offering | Oct 1, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2025 | Other filings | SEC |
| S-1 · Registration statement | Sep 29, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 26, 2025 | Current report | SEC |
| 8-K · Current report | Sep 18, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Sep 15, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Sep 15, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Sep 15, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 5, 2025 | Meeting notice | SEC |
| 8-K · Current report | Sep 5, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 26, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 21, 2025 | Other filings | SEC |
| DEF 14A · Proxy statement | Aug 18, 2025 | Meeting notice | SEC |
| S-3 · Registration statement | Aug 15, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | Aug 6, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 24, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jul 22, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 17, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jul 14, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 9, 2025 | Management or board change | SEC |
| DRS · Draft registration statement | Jul 2, 2025 | Offer document | SEC |
| RW · Request to withdraw a registration | Jun 11, 2025 | Other filings | SEC |
| S-1 · Registration statement | May 27, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| DRS · Draft registration statement | May 5, 2025 | Offer document | SEC |
| 8-K · Current report | May 2, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Dec 17, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 17, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 17, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 17, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 16, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Dec 13, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Dec 13, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 13, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 11, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 11, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 10, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 10, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 9, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Dec 5, 2024 | Offer document | SEC |
| FWP · Free writing prospectus | Nov 22, 2024 | Offer document | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| S-1/A · Registration statement, amended | Nov 21, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | Nov 4, 2024 | Other filings | SEC |
| S-1 · Registration statement | Oct 30, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 27, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | May 22, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 22, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 22, 2024 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | May 20, 2024 | Other filings | SEC |
| 424B3 · Prospectus | May 17, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | May 16, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | May 15, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 14, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2024 | Management or board change | SEC |
| D | May 10, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| S-3 · Registration statement | May 8, 2024 | Offer document | SEC |
| 8-K · Current report | May 3, 2024 | Material contract | SEC |
| 8-K · Current report | Apr 10, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 8, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Apr 5, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 5, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Apr 3, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 3, 2024 | Other filings | SEC |
| S-3 · Registration statement | Mar 29, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 29, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 27, 2024 | Results | SEC |
| 10-K · Annual report | Mar 26, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 6, 2024 | Management or board change | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Palisade Bio, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 179,277,820
- Fully diluted
- 179,277,820
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 179,277,820 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 179,277,820 |
| Sep 30, 2026 | 174,442,971 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Catherine Angell Sohn Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Altimmune, Inc. (Director · Since at least Mar 23, 2023); Axcella Health Inc (Director · Aug 21, 2019 – May 19, 2022 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Lifecore Biomedical, Inc. (Director · Nov 13, 2012 – Jun 4, 2022 · Past); Jazz Pharmaceuticals plc (Director · Jul 27, 2012 – Aug 11, 2023 · Past) | Director · Jan 13, 2014 – Jul 1, 2015 · Past |
| Mary Ann Gray Other companies: BioAtla, Inc. (Director · Since at least Jun 16, 2022); Keros Therapeutics, Inc. (Director · Since at least Jun 1, 2022); Compass Therapeutics, Inc. (Director · Since at least Apr 26, 2022); RAPT Therapeutics Inc (Director · Since at least Mar 31, 2022) | Director · Jun 11, 2023 – Nov 21, 2023 · Past |
| Robert Baltera Jr Other companies: Imago Biosciences Inc (Director · Jul 15, 2021 – Jan 11, 2023 · Past); Frazier Lifesciences Acquisition Corp (Director · Dec 8, 2020 – Nov 22, 2022 · Past); Xencor, Inc. (Director · Dec 2, 2013 – Jun 23, 2016 · Past); VivoSim Labs, Inc. (Director · Mar 13, 2012 – Jul 26, 2018 · Past) | Director · Since at least Jun 10, 2026 |
| James R. Neal Other companies: Akari Therapeutics PLC (Director · Since at least Nov 14, 2024); Processa Pharmaceuticals, Inc. (Director · Since at least Jul 19, 2022); Monterey Bio Acquisition Corp (Director · Sep 30, 2021 – Sep 30, 2021 · Past) | Director · Apr 27, 2021 – Feb 9, 2024 · Past |
| Donald A. Williams Other companies: Akari Therapeutics PLC (Director · Jan 1, 2024 – Jun 28, 2024 · Past) | Director · Since at least Jun 10, 2026 |
| Jones Jonathan Brian Lloyd Other companies: Juniper Pharmaceuticals Inc (Vice President & CFO · Jan 15, 2013 – May 5, 2014 · Past) | Chief Financial Officer · May 18, 2015 – Mar 24, 2017 · Past |
| William Clyde Oldaker Other companies: WashingtonFirst Bankshares Inc (Director · Jan 1, 2018 – Jan 1, 2018 · Past) | Director · Jul 2, 2018 – Jul 1, 2019 · Past |
| Adarsh Patel | Head of Chemistry, Manufacturing and Controls (CMC) · Since at least Nov 4, 2026 |
| Binxian Wei | Director · Since at least Jun 10, 2026 |
| Daniel J. Larkins | Head of Global Regulatory Affairs · Since at least Nov 4, 2026 |
All 26 people
| Person | Seat |
|---|---|
| Dawn Louro | Head of Clinical Operations · Since at least Nov 4, 2026 |
| Emil Chuang | Director · Since at least Jul 7, 2025 |
| James Izanec | Head of Clinical Development · Since at least Sep 28, 2026 |
| JD Finley | Chief Executive Officer and Director · Since at least Oct 28, 2026 |
| Joerg Heyer | Head of Translational Science and Medicine · Since at least May 1, 2025 |
| John David Finley | CEO CFO, Director · Since at least Apr 29, 2022 |
| Jordan Zwick | Director · Since at least Jun 10, 2026 |
| Julien E. Capers | See Remarks · Since at least Oct 19, 2026 |
| Kenneth C Carter | Executive Chairman, Director · Dec 12, 2018 – Dec 12, 2018 · Past |
| Mitchell Lawrence Jones | See Remarks · Since at least Sep 4, 2025 |
| Mitch Jones | President and Chief Medical Officer · Since at least Oct 28, 2026 |
| Ramesh Donthamsetty | Head of IR and Corporate Strategy · Since at least Nov 4, 2026 |
| Robert Baltera | Director · Since at least Jul 10, 2026 |
| Robert J Trenschel | Director · Apr 27, 2021 – Feb 8, 2024 · Past |
| Ryker Willie | Head of Finance and Corporate Controller · Since at least Nov 4, 2026 |
| Stephanie Diaz | Director · Apr 27, 2021 – Feb 8, 2024 · Past |
Log in to ask 6ix AI your own questions about Palisade Bio, Inc.